Connect with us

Technology

Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist

Published

on

Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of partner surgical facilities.The program will compare postoperative outcomes (opioid utilization, length of stay, and patient-reported pain) between standard of care and procedures using VectorMist and The LASSO Protocol.The parties have agreed to explore extending the same evidence architecture across Vector’s broader portfolio, including its peptide therapeutics programs, subject to a separate agreement.

MEQUON, Wis. and SAN FRANCISCO, July 17, 2026 /CNW/ — Vector Science & Therapeutics Corp. (TSXV: PAIN) (“Vector”) and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting VectorMist™, Vector’s localized atomized drug delivery platform, and The LASSO Protocol™ (Laparoscopic Atomization System for Sparing Opioids).

VectorMist is designed to deliver atomized medication directly to the surgical site during laparoscopic procedures, providing targeted pain control at the source and reducing reliance on systemic opioids in postoperative recovery. The LASSO Protocol is the clinical protocol built on the VectorMist platform.

Under the agreement, Caresyntax will design and operate a multi-phase real-world evidence program across a network of partner surgical facilities. The program begins with baseline data collection on current standard-of-care procedures, capturing postoperative opioid utilization, length of stay, and patient-reported pain scores. A comparative phase then measures outcomes from VectorMist procedures against that baseline. The program culminates in a prospective comparative registry across the participating surgical network, giving institutions the ability to benchmark their outcomes against peer and cohort performance on a standardized data model.

The partnership positions VectorMist as a data-enabled surgical platform rather than a device-only offering. Every institution deploying VectorMist will contribute to and benefit from a growing body of real-world outcomes evidence, a value proposition aligned with the outcomes accountability that hospital purchasing committees and value-based care programs now require.

The parties have also agreed to explore extending the evidence architecture beyond VectorMist. Vector and Caresyntax intend to evaluate applying the same approach (standardized data capture, comparative analysis, and registry-based benchmarking) across Vector’s broader portfolio, including its peptide therapeutics programs. A common evidence infrastructure would allow each program to draw on shared methodology, data governance, and clinical network rather than standing up parallel data efforts. Any such expansion would be subject to a separate agreement between the parties.

“Every surgical procedure should generate evidence that makes the next one better,” said Dr. Brad Worthington, Chief Medical Officer of Vector. “This partnership builds that feedback loop into VectorMist from day one. Rigorous, comparative real-world evidence on opioid utilization, length of stay, and patient-reported pain is how we earn the confidence of surgeons and the institutions they serve.”

“Vector is doing what the next generation of medtech companies must do — building the evidence engine alongside the product,” said Dr. Bruce Ramshaw, Chief Medical Informatics Officer of Caresyntax. “By applying our clinical quality improvement methodology from the very first case, this program will give surgeons and institutions a continuous, comparative view of real-world performance and turn every VectorMist procedure into measurable clinical insight.”

The real-world evidence program directly supports Vector’s thought leadership and clinical education strategy for The LASSO Protocol, including a planned white paper series establishing sustained opioid sparing as a distinct clinical category.

About Vector Science & Therapeutics Corp.

Vector Science & Therapeutics Corp. is a medical technology and therapeutic delivery company developing technologies intended to improve how pharmaceutical agents, peptides, biologics and other therapeutic compounds are delivered to target tissues.

The Company’s intellectual property portfolio spans advanced transdermal delivery, precision catheter systems, localized pain management, regenerative medicine, pancreatic oncology, smart wound care, lyophilized pharmaceutical systems and next-generation therapeutic delivery technologies.

Vector Science & Therapeutics Corp. is headquartered in Mequon, Wisconsin.

About Caresyntax

Caresyntax powers surgical performance and outcomes through AI-enabled analytics, real-world evidence, and workflow integration tools. Its regulatory-grade platform supports health systems, payers, and life sciences companies globally. To learn more visit www.caresyntax.com/rwe

Forward-Looking Statements

This press release contains forward-looking statements concerning Vector Science & Therapeutics Corp.’s intellectual property, technology platforms, development programs, potential clinical applications, strategic opportunities and commercialization plans. These statements are based on current expectations and are subject to risks and uncertainties. Technologies described by the Company may require additional research, development, preclinical or clinical evaluation and applicable regulatory review before commercialization.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/vector-science–therapeutics-and-caresyntax-announce-real-world-evidence-partnership-for-vectormist-302828324.html

SOURCE Vector Sciences & Therapeutics

Continue Reading

Technology

Leo Cancer Care Brings Into Clinical Use an Upright Radiotherapy Platform Cleared for Use With Any Radiation Beam

Published

on

By

Upright. From Concept to Clinical Reality

BOSTON, Sept. 27, 2026 /PRNewswire/ — Leo Cancer Care is marking a defining moment for radiation oncology as upright radiotherapy moves from concept to clinical reality.

The Upright Platform is designed to be beam-agnostic and cleared for integration with both particle- and photon-compatible fixed-beam technologies, offering health networks unprecedented choice rather than being restricted to one beam manufacturer or treatment configuration.

A Flexible, Now Clinically Available Platform Built for the Future

Following the first clinical treatment using Leo Cancer Care’s Marie® upright patient positioning and imaging system in June 2026, patients can now receive radiotherapy in an upright position. Enabled by a partnership with Mevion Medical System, utilising their compact, fixed-beam proton accelerator and powered by RayStation®, the treatment planning system from RaySearch Laboratories.

While this represents an important clinical milestone, the potential of Leo Cancer Care’s upright technology extends beyond one installation or treatment configuration. Its flexible platform creates opportunities for clinicians and technology partners to explore compliant IGRT system combinations around the needs of their patients, infrastructure and services.

Expanding Access to Upright Photon Radiotherapy

While Leo Cancer Care’s initial product offering, the Marie® solution, is 510(k) cleared and CE marked  to be integrated with any fixed beam, including conventional photon therapy, the company revealed development of a dedicated fixed-beam photon platform of its own (subject to regulatory clearance), at ASTRO 2025. This platform would integrate upright patient positioning, imaging and a fixed photon beam. Treating with photons in the upright position has the potential to offer greater patient choice while enabling more compact radiotherapy solutions that could help expand access to high-quality cancer care.

This next future innovation represents an important step towards bringing upright positioning and imaging into conventional radiotherapy and changing how photon treatment services are designed and delivered. This new method is already being utilized in new proton therapy installations where health networks are adopting a treatment delivery solution that was not so long ago widely questioned.

One Upright Environment. One Consistent Workflow. A Single Source of Truth.

Leo Cancer Care has taken a fundamentally different approach to radiotherapy. The radiation beam remains fixed while the patient is positioned upright and slowly rotated to multiple beam angles, enabling radiation to be delivered around the target area to deliver their personalised treatment plan.

At the heart of the solution is the upright platform, connecting fan beam imaging, planning, positioning and treatment delivery around a single patient position. Because the patient is imaged in the position they are treated in, every stage of the pathway works from the same geometry, giving the clinical team one reference point to plan and verify against.

For patients, upright radiotherapy provides a treatment experience centred around a more natural position, with eye-to-eye interaction with the clinical team. It may be particularly valuable for people who find it difficult or uncomfortable to lie flat because of breathing difficulties, pain, mobility challenges or anxiety.

International research also suggests that upright positioning may support more consistent anatomical positioning and reduce organ motion for certain treatment sites. These potential benefits will continue to be investigated as more upright systems enter research and clinical use.

From Innovation to Adoption

Stephen Towe, Co-Founder and CEO of Leo Cancer Care said: “The first clinical treatment using our technology proved that upright radiotherapy is no longer simply an idea for the future. It is now a clinical reality. This milestone is only the beginning. By connecting imaging, planning, positioning and treatment delivery in the upright position, we can create a single source of truth throughout the patient’s treatment journey. Our beam-agnostic approach gives us the flexibility to work with different compatible fixed-beam technologies, helping reduce the infrastructure traditionally associated with advanced radiotherapy and supporting our ambition to expand access to high-quality cancer care.”

At the American Society for Radiation Oncology’s 2026 Annual Meeting in Boston, Leo Cancer Care will share its clinical progress and vision for the future.

The next phase will focus on building clinical evidence, supporting further installations and collaborating with healthcare and technology partners to make advanced treatment more human and accessible.

Natural anatomy. New possibilities. Think Upright.

View original content to download multimedia:https://www.prnewswire.com/news-releases/leo-cancer-care-brings-into-clinical-use-an-upright-radiotherapy-platform-cleared-for-use-with-any-radiation-beam-302890849.html

SOURCE Leo Cancer Care

Continue Reading

Technology

Fuse Oncology to Showcase S!GNAL Workflow Experience at ASTRO 2026

Published

on

By

Potential workflow illustrates how patient workflow coordination in GE HealthCare’s Intelligent Radiation Therapy™ (iRT) software solution could connect to targeted charge review in S!GNAL

BOONE, N.C., Sept. 27, 2026 /PRNewswire/ — Fuse Oncology today announced plans to showcase a potential workflow experience with GE HealthCare’s Intelligent Radiation Therapy™ (iRT) software solution at the ASTRO 2026 Annual Meeting. The concept illustrates how iRT could launch S!GNAL, Fuse Oncology’s charge capture solution, from the patient workflow using patient information. This could provide users a direct path from workflow coordination in iRT to targeted charge review in S!GNAL while preserving patient context and reducing manual handoffs between systems.

Radiation oncology teams often work across multiple systems that rarely connect, such as EMR, OIS, treatment planning, and billing systems. iRT is an AI-supported software solution for radiation therapy workflow management designed to connect tools, coordinate workflows, and reduce manual handoffs to help patients progress from diagnosis to treatment more efficiently. The potential experience with S!GNAL illustrates how that coordinated workflow could extend to targeted charge review, a capability planned for a future iRT release.

Charge capture in radiation oncology is a distributed problem. A missing IGRT image, an untagged physics consult, or an inconsistent weekly treatment management charge typically comes to light weeks after the service, once the clinical context has gone cold. Correcting it means revisiting old records, reconstructing physician intent, and coordinating between clinical and billing teams — and that is only for the errors that surface at all.

S!GNAL reviews charge data daily and flags missed or miscoded charges within 24 hours of service, rather than surfacing them in a retrospective audit weeks later. Its rule logic covers every category of radiation oncology code, including the ones that carry the most impact: missed treatment fractions, weekly physics, weekly treatment management, and dosimetry planning. S!GNAL evaluates planning charges against the discrete data in the treatment planning system rather than inferring them from a document’s name or a predetermined template, then uses natural language processing to check those expectations against what the clinical documents say. In a multi-site organization S!GNAL is installed once and configured separately for each location, so a freestanding clinic and a hospital-based department are each reviewed against the rules that apply to them.

In a deployment across 15 sites of an 18-site radiation oncology network, S!GNAL surfaced $1,092,202 in missed treatment delivery and IGRT charges between July 2024 and March 2025, each identified within 24 hours of service. Charge lag fell by more than 30 days.

“Every clinic we talk to has the same problem, and almost none of them have the staff to solve it by auditing harder. The fix is to put the detection where the work already happens, in the system the team is already in. Every hour a billing or clinical team spends chasing last month is an hour not spent moving a patient toward treatment,” said James Bauler, Chief Executive Officer, Fuse Oncology.

The potential workflow experience is planned to be shown during the ASTRO 2026 exhibit dates, September 27 to 29 in Boston. Fuse Oncology will be at booth 2533. The capability is currently being developed and evaluated for potential future commercial availability, with further details to be announced at a later date.

About Fuse Oncology

Fuse Oncology is a healthcare technology company focused on radiation oncology, delivering the operational layer for the clinical and administrative workflow. Fuse delivers SaaS solutions that break down healthcare workflow and data silos to create a seamless experience for clinicians. By placing the broader electronic medical record system at the center of the architecture, Fuse eliminates duplicative and inefficient efforts to enable a future where oncology care moves at the speed of patients. For more information, visit FuseOnc.com. Stay updated on our latest developments by following us on LinkedIn @fuseoncology.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fuse-oncology-to-showcase-sgnal-workflow-experience-at-astro-2026-302890548.html

SOURCE Fuse Oncology, Inc.

Continue Reading

Technology

Best Prescription Sunglasses (2026): Quay Featured Among Stylish, Fashion-Forward RX Frames for Everyday Wear and Versatile Personal Style by Consumer365

Published

on

By

NEW YORK, Sept. 27, 2026 /PRNewswire/ — Consumer365 has recognized Quay in a 2026 feature examining the best prescription sunglasses for everyday wear and versatile personal style. The coverage highlights prescription-ready fashion frames, varied lens options, and published prices relevant to shoppers seeking premium-looking eyewear within a defined budget.

Best Prescription Sunglasses:

Quay – offers prescription-ready sunglasses with fashion-focused frames, customizable lens tints, and adjustable or built-in nose pads, combining premium-looking designs with everyday versatility and personal style.

The feature focuses on Quay’s online prescription sunglasses collection. The range includes aviators, squares, rounds, and cat eyes, supported by filters for frame size and bridge fit. The selection allows different silhouettes to be considered alongside practical requirements for vision correction, comfort, and daily use.

Consumer365’s assessment draws on published product specifications and ordering guidance. The coverage examines accessible luxury as a styling approach, with attention to frame proportions, finishes, and customization. The review also explains why the complete prescription configuration matters when evaluating price and suitability.

Prescription Frames With Distinct Design Details

The featured collection includes several interpretations of contemporary prescription eyewear. Three models illustrate how frame shape, construction, and bridge design create different styling options:

GONE VIRAL RX: A small oval aviator combines metal construction with an integrated hinge and a clean temple design. The narrow-fit frame uses adjustable silicone nose pads and provides slightly smaller coverage.WIRED RX: An oversized unisex square features rounded corners, lightweight construction, and built-in nose pads. The softened outline gives the frame a relaxed profile for everyday styling.AURA POINTS RX: A narrow oval frame combines standard arms with built-in nose pads. Published measurements include a 141 mm frame width and a 35 mm lens height, creating a compact visual profile.

Each featured model includes a hard case and cleaning cloth. Together, the designs demonstrate how prescription-ready frames can vary in material, scale, bridge support, and overall silhouette.

Premium-Looking Eyewear and Budget Considerations

At the time of research, Quay‘s US product pages displayed AURA POINTS RX at $75, WIRED RX at $85, and GONE VIRAL RX at $175. The figures provide reference points for browsing. The displayed amounts should not be treated as guaranteed totals for every prescription configuration.

Lens material and selected options can affect the completed purchase. A meaningful budget assessment therefore considers the full frame-and-lens configuration. Comparing models at the same prescription settings provides a clearer basis for evaluating value.

The different displayed prices show that Quay’s prescription collection covers more than one price level. AURA POINTS RX and WIRED RX provide lower starting points, while GONE VIRAL RX sits at a higher listed price. Selection can therefore depend on silhouette, frame material, bridge fit, and preferred finish, subject to the final lens configuration.

The accessible-luxury angle centers on appearance rather than a claim of luxury-grade construction. Metallic accents, tortoise patterns, and considered proportions contribute to a polished look. Consumer365’s feature separates those visual qualities from measurable considerations such as prescription compatibility and frame dimensions.

Lens Materials and Sun Tint Options

Quay‘s featured RX pages list single-vision polycarbonate, 1.67 high-index, and 1.74 ultra-high-index lens options. Published specifications identify anti-reflective coating, scratch resistance, and 100% UVA/UVB protection across the listed choices. Blue light filtering is also available as an optional add-on. Availability should be confirmed for the selected frame and prescription.

Sunglass tint options include Black Fade, Brown Gradient, Smoke Solid, Green, and Navy. Light Blue, Pink, and Purple provide further color choices. Lens tint can change the appearance of a frame without changing the underlying silhouette.

Quay notes that prescription lens colors may differ slightly from their nonprescription versions. Product photographs should be considered alongside the selected prescription tint before an order is completed.

Quay’s prescription guidance identifies polarization as an available sunglass option for polycarbonate and 1.67 high-index lenses. Tint selection and polarization should be reviewed separately during configuration, rather than assumed to be interchangeable features.

Prescription strength can influence the finished appearance, but Quay’s prescription lenses use an aspherical design that helps keep them on the thinner side. Frame size and lens material can still affect the final profile. Guidance from an optical professional can help assess lens material and frame proportions together, supporting a configuration that accommodates both the prescription and the intended style.

Fit and Prescription Requirements

Published measurements provide a practical starting point for comparing frames. WIRED RX lists a 144 mm frame width, an 18 mm bridge, and 148 mm temples. Comparing those dimensions with a comfortable existing pair can help narrow the selection.

Virtual try-on appears on the featured product pages. The tool supports visual comparisons but cannot establish physical comfort during extended wear. Quay’s fitting guidance recommends matching frame width to face width and avoiding pressure around the nose, ears, and cheekbones.

Online purchases require an unexpired eyeglass prescription and pupillary distance. Contact lens prescriptions cannot be used to order prescription glasses. Pupillary distance helps position the lenses appropriately relative to the eyes.

Quay currently offers single-vision prescription glasses and sunglasses online. Progressive lenses are available through select stores and authorized dealers. The ordering route therefore depends on the required lens type, alongside the chosen frame and prescription details.

Ordering and Everyday Ownership

Quay advises allowing up to three weeks for completed prescription orders. Custom production can require up to two weeks before shipping confirmation. Planning around the prescription timeline is relevant when eyewear is needed for travel or another scheduled occasion.

Online prescription purchases are generally final sale. Limited remake provisions apply, including a complimentary lens remake when a doctor updates or revises a prescription. Requests must be made within 30 days of delivery and require supporting documentation.

Quay recommends cleaning lenses with a microfiber cloth and lens cleaner. Product guidance advises against using paper towels or clothing. The included case provides storage between wears.

Consumer365’s recognition brings attention to Quay’s combination of prescription-ready designs and configurable sun lenses. The feature encourages evaluation of appearance, fit, prescription requirements, and complete pricing together, providing a practical framework for selecting eyewear suited to everyday use.

The full review is available at the Consumer365 website.

About Quay

Quay is a global eyewear brand offering a wide selection of sunglasses and prescription glasses. The company’s collections emphasize contemporary design, functional lens features, and pricing that remains accessible to a broad range of consumers. Quay products are available through its direct-to-consumer website, Quay stores and select retail partners worldwide.

About Consumer365.org: Consumer365 provides consumer news and industry insights. As an affiliate, Consumer365 may earn commissions from sales generated using links provided.

View original content:https://www.prnewswire.com/news-releases/best-prescription-sunglasses-2026-quay-featured-among-stylish-fashion-forward-rx-frames-for-everyday-wear-and-versatile-personal-style-by-consumer365-302890245.html

SOURCE Consumer365.org

Continue Reading

Trending